Ipsen Stock
Ipsen Stock price
Key metrics
Is Ipsen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
Ipsen Stock Analysis
Analyst Opinions
19 Analysts have issued a Ipsen forecast:
Analyst Opinions
19 Analysts have issued a Ipsen forecast:
Financial data from Ipsen
| Dec '24 |
+/-
%
|
||
| Revenue | 3,575 3,575 |
8%
8%
|
|
| Gross Profit | 2,956 2,956 |
8%
8%
|
|
| EBITDA | 1,498 1,498 |
121%
121%
|
EBIT (Operating Income) EBIT | 792 792 |
34%
34%
|
| Net Profit | 346 346 |
46%
46%
|
|
In millions EUR.
Don't miss a Thing! We will send you all news about Ipsen directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
| Head office | France |
| CEO | David Loew |
| Employees | 5,358 |
| Founded | 1998 |
| Website | www.ipsen.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
